EN DE
STOCK COMPARISON

Seoul Pharma Co. vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Seoul Pharma Co. (018680) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Seoul Pharma Co. trades at KRW 1,987 versus a fair value of KRW 905 (-54%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).
Seoul Pharma Co.
018680.KQ · KRW · Energy
-54%
upside to fair value
overvalued
PriceKRW 1,987
Fair ValueKRW 905
Quality53/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.18
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Seoul Pharma Co.Jiangsu Hengrui Medicine Co
Valuation
—P/E (TTM)43.6×
—P/S (TTM)10.84×
—P/B5.76×
—EV/EBITDA33.0×
—PEG0.93×
—Dividend yield0.4%
—Dividend per share¥0.20
Profitability
1%Net margin25%
-2%Operating margin32%
2%Return on equity15%
-1%Return on assets9%
Growth
-6%Revenue growth (YoY)13%
1.4%Avg. growth/yr (3Y)13.9%
0.0%Avg. growth/yr (5Y)2.5%
Balance & size
0.24×Debt / equity—
$17MMarket cap$52B
weakGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 0 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Seoul Pharma Co.of which business quality 54 · market factors 27 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 47
ProfitabilityMargins and returns on capital today
38
63
Quality GrowthAre margins and returns improving?
31
41
CashflowEarnings quality: real cash, not paper profit
44
82
Fin. StrengthBalance sheet, leverage, solvency risk
60
100
InvestmentDisciplined investing over empire-building
84
27
Low VolatilityCalm price path (market factor)
81
78
MomentumPrice trend over the last 3–12 months (market factor)
5
37
52W MomentumDistance to the 52-week high (market factor)
3
29
Net IssuanceBuybacks instead of dilution
82
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Seoul Pharma Co.

DCF ModelsKRW 1,032
Earnings-BasedKRW 780
MultiplesKRW 1,099
Asset-BasedKRW 2,359
Growth DCFKRW 1,162
Economic ProfitKRW 2,328
Growth EarningsKRW 698

16 of 19 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Seoul Pharma Co.
Bear KRW 679Fair Value KRW 905Bull KRW 1,131
KRW 1,987 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.18 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Seoul Pharma Co. · Energy

Quality score53 · above median
Fair value upside-54% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Seoul Pharma Co. trades at KRW 1,987 versus a fair value of KRW 905 (-54%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
Seoul Pharma Co. · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Seoul Pharma Co.

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs Toyota Motor Corporation

Related to Jiangsu Hengrui Medicine Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.